China's human genetic resources information is provided or open to the outside world

Filing Scope and Procedure

1. Scope of filing

Applicable to the transfer of human genetic resources information to foreign organizations, individuals and their establishment or

Provided or open to use by an agency that actually controls.

The applicant unit should be a Chinese unit.

2. Filing procedures

(1) Applicants log in to the online platform (website: https://202.108.211.75)

Submit the information backup, confirm that the backup is successful, and obtain the information backup number.

(2) After the information is backed up successfully, the applicant can log in to the online platform (URL:

https://grats.most.gov.cn) submit the filing materials online to get the filing number.

(3) After the applicant has obtained the record number, the information of human genetic resources can be sent to foreign countries.

Organizations, individuals and institutions established or actually controlled by them provide or open for use.

3. Filing materials

| Serial numb | er Name of submitted material | data type | Require | | | |
|---|--|----------------|--|--|--|--|
| 1 | Filing Information Form | The signatur | e and seal of the electronic unit signature page. | | | |
| 2 | Legal personality materials electronic | | Legal person qualification materials include enterprise legal person business license or institution legal person certificate or private non-enterprise Industry unit registration certificate, etc. | | | |
| 3 | China Human Genetic Resources International Cooperative scientific research approval decision Book | Electronic, if | involved, shall be provided. | | | |
| Note: Please refer to Attachment 1-2 for the template of the filing information form. | | | | | | |

1

attachment1

Chinese human genetic resource information provides or opens to use

Filing Information Form

(provided externally)

| name: | | |
|-------------------|------|---|
| Application unit: | | |
| Contact: | | - |
| contact number: | | |
| Contact Email: | | |
| mailing address: | | |

years

Day

Ministry of Science and Technology of the People's Republic of China

Completion Instructions

- 1. The applicant unit should be a Chinese unit.
- 2. Applicants should carefully read the Regulations of the People's Republic of China on the Administration of Human Genetic Resources

"Example" "Chinese human genetic resource information provides or opens the scope of the filing and processes

Sequence", the contents of the record must meet the requirements.

3. The contents of the filing information form must be realistic, accurate and complete, and the levels are clear. Application

The person shall be responsible for the authenticity, accuracy, completeness and standardization of the filing materials.

4. The applicant fills in the filing information form online according to the prompts on the online platform. positive information

The text part should be filled in with the imitation Song Xiaoji characters, and the line spacing should be 1.5 times. Anything not filled in

content, please use "None". Foreign languages should be expressed in both the original and Chinese, and the foreign abbreviations should be used.

When it appears for the first time, the full name must be indicated.

1. Basic information table

| name | | | | | | | | |
|---|--|--|-----------------------|----------------------------|------------------|-----|-----|--|
| Information backup number | | | | | | | | |
| Sources of information on human genetic resources | | ÿ International cooperation scientific research on human genetic resources, approval decision book number/filing number: ÿ A non -human genetic resource international cooperation scientific research | | | | | | |
| Ways t | to provide external ÿNetwo | rk transmission ÿPhys | sical storage mediun | n ÿOther (please sp | ecify) | | | |
| exte | rnal time | | Year-Month to | o Year-Month | _ | | | |
| | name | | | Social Unified Credit Code | | | | |
| | legal representative | | | Competent department | | | | |
| | unit location | Provir | nce (Municipality, M | unicipality) Postal C | ode | | | |
| Application | ^{on unit} mailing address | | | | | | | |
| | Unit Type | ÿScientific research ÿOther (please spec | | iities ÿMedical institu | utions ÿEnterpri | ses | | |
| | Name | | gender | | date of | yea | ars | |
| | company name | | | | | | | |
| principa | | ÿ Deputy Senior ÿ Inte | ermediate ÿ Primary | ÿ Others | | | | |
| | position | | business expertise | | | | | |
| | contact number | | E-mail | | | | | |
| | | Chinese | | | | | | |
| | name | English sentence | | | | | | |
| Information y can be added y | legal representative n receiving unit | | · | | | | | |
| | mailing address | | | | | | | |
| | principal | | contact number | | E-mail | | | |

2. Basic information (ÿFill in for international cooperative scientific research on non-human genetic resources)

Basic information on human genetic resources to be provided externally (type, size, source of human genetic resources information, etc., fill in the table below)

| C number | of sequence information types | Unit/ Specificat | Detection unit ion |
|----------|-------------------------------|---------------------|-----------------------|
| | | | |
| | | | |
| | | | |

Note: 1. Information type: clinical data, such as demographic information, general laboratory examination information, etc.; imaging data, such as B-ultrasound, CT,

PET-CT, MRI, X-ray, etc.; biomarker data such as diagnostic biomarkers, surveillance biomarkers, drug

Efficacy/response biomarkers, predictive biomarkers, prognostic biomarkers, safety biomarkers, susceptibility/risk

Biomarkers; genetic data such as whole genome sequencing, exome sequencing, target region sequencing, human mitochondrial sequencing, whole genome sequencing

 $Genome\ methylation\ sequencing,\ Inc\ RNA\ sequencing,\ transcriptome\ sequencing,\ single-cell\ transcriptome\ sequencing,\ small\ RNA\ sequencing,\ etc.;\ protein$

data; metabolic data;

2. Total number of cases: Case, unit/specification: MB/case.

Biomarker data information situation

| serial number | Biomarkers object name | total | unit/ Specification | Biomarker Data category | Detection unit |
|---------------|---------------------------|-------|------------------------|----------------------------|----------------|
| | | | | | |
| | | | | | |
| | | | | | |

 $Notes: 1.\ Biomarker\ data\ categories:\ diagnostic\ biomarkers,\ monitoring\ biomarkers,\ pharmacodynamic/response\ biomarkers,\ pha$

 $\label{predictive} Predictive\ biomarkers,\ prognostic\ biomarkers,\ safety\ biomarkers,\ susceptibility/risk\ biomarkers;$

 $2.\ Total\ number\ of\ cases:\ Case,\ unit/specification:\ MB/case.$

| ge | genetic data information | | | | | | | | | |
|------|--------------------------|---|-----------------------------|---------------------------------------|---|--|--|--|--|--|
| | Sequence | Number Sequencing Type S | Sequencing Depth | Sequencing platform (device model) | Sequencing unit | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| 2 | | | | | | | | | | |
| 8 | | | | | | | | | | |
| No | to: 1. Seguen | ning type; whole geneme cogu | lancing every coguencing to | get region coguencing, human mitochoo | ndrial sequencing, whole genome methylation | | | | | |
| | | | | ranscriptome sequencing, small RNA se | | | | | | |
| | | | | tained by sequencing to the genome | size (Genome); | | | | | |
| | | sting platform lists the device mo uencing platform: Bioel | | and Kang NextSeq CN500, M | GI | | | | | |
| М | GISEQ-20 | 0, MGI MGISEQ-2000, | MGI MGISEQ-T7, Illum | nina MiseqDx, Illumina MiSeq, | | | | | | |
| Illu | umina Nex | tSeq 550, Illumina HiSe | eq 3000, Illumina HiSeq | 4000, Illumina NovaSeq 6000 |) Download | | | | | |
| Ar | n DA8600, | others (with instruction | is). | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |

3. Risk Analysis and Countermeasures

| (Explain the security protection measures, capabilities and levels of the information receiving unit; possible risks include but are not limited to the | e risks |
|---|---------|
| of information being leaked, damaged, tampered, abused after external provision and re-transfer, and the analysis and countermeasures of possi | ble |
| intellectual property disputes) | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

4. Schedule for the external provision of human genetic resources information

| Serial num | ber information type | total | unit/ | information reception unit | Storage location/ UR | Ways to provide externally | use | final disposal |
|------------|----------------------|-------|-------|----------------------------|-------------------------|----------------------------|-----|----------------|
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |

Note: 1. Information type: clinical data, such as demographic information, general laboratory examination information, etc.; imaging data, such as B-ultrasound, CT, PET-CT, MRI, X-ray, etc.; biomarker data, such as diagnostic

Disruptive biomarkers, surveillance biomarkers, pharmacodynamic/response biomarkers, predictive biomarkers, prognostic biomarkers, safety biomarkers, susceptibility/risk biomarkers;

Data such as whole genome sequencing, exome sequencing, target region sequencing, human mitochondrial sequencing, whole genome methylation sequencing, lnc RNA sequencing, transcriptome sequencing, single-cell transcriptome sequencing, small RNA sequencing, etc.; protein data; metabolic data;

- 2. Total number of cases: case, unit/specification: MB/case;
- 3. Methods of external provision: network transmission; physical storage medium; other, (with instructions);
- 4. Final disposal method: Destruction; Temporary storage (Storage time:); Others (with instructions).

5. Unit signature

| Unit opinion: |
|--|
| This unit is in accordance with the "Scope of Recordation for the External Provision or Open Use of China's Human Genetic Resources Information and |
| Procedures, and carefully read and understand the Regulations of the People's Republic of China on the Administration of Human Genetic Resources |
| On the basis of relevant laws and regulations, strictly fulfill the legal person responsibility system and submit the filing materials. hereby solemnly accept |
| promise: |
| 1. The authenticity, integrity, normative, and number of the entire content of the recorded materials |
| Review according to the accuracy of the information, and there is no false report, concealment or omission; |
| 2. The filing materials comply with relevant laws such as the Regulations of the People's Republic of China on the Administration of Human Genetic Resources |
| Laws and regulations; |
| 3. Provide information on Chinese human genetic resources to the outside world in strict accordance with the contents of the record; |
| 4. There is no intellectual property dispute in the information provided to the outside world. |
| |
| |
| |
| |
| |
| |
| |
| Signature of legal representative: (must have signature) |
| Unit official seal: (must have stamp) |
| year month day |
| |
| |

Attachment list

| serial number | appendix |
|---------------|---|
| 1 Docum | ents on legal personality |
| 2 Approva | al Decision for International Collaborative Scientific Research |

Annex 2

Filing Information Form

(open for use)

| name: | |
|-------------------|---|
| Application unit: | _ |
| Contact: | |
| contact number: | |
| Contact Email: | _ |
| mailing address: | |

year month day

Ministry of Science and Technology of the People's Republic of China

Completion Instructions

- 1. The applicant unit should be a Chinese unit.
- 2. Applicants should carefully read the Regulations of the People's Republic of China on the Administration of Human Genetic Resources

"Example", "Scope and Procedure of Recordation for the External Provision or Open Use of Human Genetic Resources in China"

Sequence", the contents of the record must meet the requirements.

3. The content of the filing information table must be realistic, accurate and complete, and clear. Application

People must be responsible for the authenticity, accuracy, integrity, and standardization of the filing materials.

4. The applicant fills in the filing information form online according to the prompts on the online platform. positive information

The text part should be filled in with the imitation Song Xiaoji characters, and the line spacing should be 1.5 times. Anything not filled in

content, please use "None". Foreign languages should be expressed in both the original and Chinese, and the foreign abbreviations should be used.

When it appears for the first time, the full name must be indicated.

1. Basic information table

| name | | | | | | | | |
|---|-------------------------------------|--|-----------------------|-------------------------------|---------------|--|--|--|
| Information backup number | | | | | | | | |
| Sources of information on human genetic resources | | ÿInternational cooperative scientific research of human genetic resources, approval decision document number/record number: ÿInternational cooperative scientific research of non-human genetic resources | | | | | | |
| Open to use | | ÿThesis publication, the title of the paper:, Journal: , ÿThe publication of the thesis, the name of the thesis: ÿInformation platform sharing, platform URL: ÿConference release, conference, meeting time: year month day name: ÿOthers (please specify) | | | | | | |
| | name | | | Social Unified Credit Code | | | | |
| | legal representative | | | Competent department | | | | |
| | unit location | Province | (Municipality, | Municipality) Pos | stal Code | | | |
| Applicati | ^{ion unit} mailing address | | | | | | | |
| | Unit Type | ÿScientific research institutions ÿUniversities ÿMedical institutions ÿEnterprises ÿOther (please specify) | | | | | | |
| | Name | | gender | | date of birth | | | |
| | company name | | | | | | | |
| | | Deputy Senior ÿ Intermediate ÿ Primary ÿ Other | | | | | | |
| princip | position | | business expertise | | | | | |
| | contact number | | E-mail | | | | | |

2. Basic information (ÿFill in for international cooperative scientific research on non-human genetic resources)

Basic information on human genetic resources to be used openly (type, size, source, etc. of human genetic resources information, fill in the table below)

| Serial num | per information type total number | of cases | Unit/ Specificat | Detection unit ion |
|------------|-----------------------------------|----------|---------------------|-----------------------|
| | | | | |
| | | | | |
| | | | | |

Note: 1. Information type: clinical data, such as demographic information, general laboratory examination information, etc.; imaging data, such as B-ultrasound, CT,

PET-CT, MRI, X-ray, etc.; biomarker data such as diagnostic biomarkers, surveillance biomarkers, drug

Efficacy/response biomarkers, predictive biomarkers, prognostic biomarkers, safety biomarkers, susceptibility/risk

Biomarkers; genetic data such as whole genome sequencing, exome sequencing, target region sequencing, human mitochondrial sequencing, whole genome sequencing

Genome methylation sequencing, Inc RNA sequencing, transcriptome sequencing, single-cell transcriptome sequencing, small RNA sequencing, etc.; protein data; metabolic data;

2. Total number of cases: Case, unit/specification: MB/case.

Biomarker data information situation

| serial number | Biomarkers object name | total number of cases | unit/ Specification | Biomarker Data category | Detection unit |
|---------------|---------------------------|--------------------------|------------------------|----------------------------|----------------|
| | | | | | |
| | | | | | |
| | | | | | |

 $Notes: 1.\ Biomarker\ data\ categories:\ diagnostic\ biomarkers,\ monitoring\ biomarkers,\ pharmacodynamic/response\ biomarkers,\ data\ categories:\ diagnostic\ biomarkers,\ diagnostic\ biomarke$

 $\label{productive} Predictive\ biomarkers,\ prognostic\ biomarkers,\ safety\ biomarkers,\ susceptibility/risk\ biomarkers;$

2. Total number of cases: Case, unit/specification: MB/case.

| genetic data ir | nformation | | | | | | |
|-----------------|---------------------------|--------------------------------------|--|---|--|--|--|
| Sequence | Number Sequencing | Type Sequencing Depth | Sequencing platform (device model) | Sequencing unit | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Note: 1. Seque | ncing type: whole geno | me sequencing, exome sequencing, | target region sequencing, human mitocl | hondrial sequencing, whole genome methylation | | | |
| Chemical seque | encing, Inc RNA seque | ncing, transcriptome sequencing, sin | gle-cell transcriptome sequencing, small | RNA sequencing; others (with description); | | | |
| 2. Sequ | uencing depth: the rati | o of the total number of bases (bp) | obtained by sequencing to the genom | ne size (Genome); | | | |
| 3. The t | est platform lists the de | evice model; | | | | | |
| 4. Sec | quencing platform | n: BioelectronSeq 4000, Ber | ry and Kang NextSeq CN500, | MGI | | | |
| MGISEQ-20 | 00, MGI MGISEQ | -2000, MGI MGISEQ-T7, III | umina MiseqDx, Illumina MiSe | eq, | | | |
| Illumina Ne | xtSeq 550, Illumir | na HiSeq 3000, Illumina HiS | seq 4000, Illumina NovaSeq 60 | 000 Download | | | |
| An DA8600 | , others (with inst | ructions). | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

3. Risk Analysis and Countermeasures

| (Possible risks include, but are not limited to, information disclosure, damage, tampering, abuse and other risks after open use and re- | |
|--|--|
| transfer, and the analysis and countermeasures of possible intellectual property disputes) | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

4. Plan for the Open Use of Human Genetic Resources Information

| serial number | type of information | total | unit/ Specification | storage Place | store url/ | open way | use |
|---------------|---------------------|-------|---------------------|------------------|------------|----------|-----|
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

Note: 1. Information type: clinical data, such as demographic information, general laboratory examination information, etc.; imaging data, such as B-ultrasound, CT, PET-CT, MRI, X-ray, etc.; biomarker data, such as diagnostic

Disruptive biomarkers, surveillance biomarkers, pharmacodynamic/response biomarkers, predictive biomarkers, prognostic biomarkers, safety biomarkers, susceptibility/risk biomarkers;

Due to data such as whole genome sequencing, exome sequencing, target region sequencing, human mitochondrial sequencing, whole genome methylation sequencing, lnc RNA sequencing, transcriptome sequencing, single cell transcriptome sequencing, small RNA sequencing, etc.; protein data; metabolic data;

2. Total number of cases: Case, unit/specification: MB/case; 3.

Open access method: paper publication; monograph publication; information platform sharing; conference publication; others (please specify).

5. Unit signature

| Unit opinion: |
|--|
| This unit is in accordance with the "Scope of Recordation for the External Provision or Open Use of China's Human Genetic Resources Information and |
| Procedures, and carefully read and understand the Regulations of the People's Republic of China on the Administration of Human Genetic Resources |
| On the basis of relevant laws and regulations, strictly implement the legal person responsibility system and submit filing materials. Hereby solemnly |
| promise: |
| 1. This unit has confirmed the authenticity, completeness, normativeness and data of all the contents of the recorded materials. |
| Review according to the accuracy of the information, and there is no false report, concealment or omission; |
| 2. The filing materials comply with relevant laws such as the Regulations of the People's Republic of China on the Administration of Human Genetic Resources |
| Laws and regulations; |
| 3. In strict accordance with the contents of the record, open the use of Chinese human genetic resources information; |
| 4. There is no intellectual property dispute in the information that is open to use. |
| |
| |
| |
| |
| |
| |
| |
| Signature of legal representative: (must have signature) |
| |
| Unit official seal: (must have stamp) |
| year month day |
| |

Attachment list

| serial number | appendix | | | | |
|---|----------|--|--|--|--|
| 1 Documents on legal personality | | | | | |
| 2 Approval Decision for International Collaborative Scientific Research | | | | | |